Cluster D was characterized by a genomically unstable and aggressive phenotype, defined by concurrent alterations in RB1, TP53, TSC1/TSC2, and MYC amplification—changes previously associated with poor outcomes and therapeutic resistance in renal cell carcinoma [5,33]. Here, TP53 is linked to renal cell carcinoma.